The Lynx Group
Cholangiocarcinoma News

Clinical Trial Enrollment Challenges for Patients with Cholangiocarcinoma

June/July 2022, Vol 3, No 2
Reham Abdel-Wahab, MD, PhD
Director of Research
Chief Scientific Officer
Cholangiocarcinoma Foundation
Samantha Pear
Patient Advocate Volunteer
Cholangiocarcinoma Foundation

Cholangiocarcinoma (CCA) is a rare, aggressive, highly heterogeneous gastrointestinal cancer with high mortality and a rising incidence. CCA is typically asymptomatic in the early stages, resulting in frequent late-stage diagnoses with an overall poor prognosis. Surgery is the only available curative treatment approach; however, it is only effective in the early stages of the disease. Available therapeutic options for later stages are limited and offer only modest benefits. Thus, there is a desperate need for patients with CCA to gain access to clinical trials to help improve survival.

The past 2 years have seen breakthroughs in the CCA clinical trial space. Three new targeted therapies—including 2 FGFR2 inhibitors infigratinib (Truseltiq) and pemigatinib (Pemazyre) and 1 IDH1 inhibitor ivosidenib (Tibsovo)—received FDA approval after showing a significant improvement in overall patient survival and progression-free survival. Yet, despite 141 phase 1 through 4 clinical trials currently enrolling patients with CCA worldwide, inclusion and exclusion criteria are limiting, affording few patients access to cutting-edge trials.

Hence, the Cholangiocarcinoma Foundation (CCF) Research Team created a survey to evaluate clinical trial enrollment rates for patients with CCA and the barriers that limit enrollment. We shared this survey with patient and caregiver attendees at the 2021 CCF Annual Conference, and 204 attendees participated. The survey results were presented at the 2022 American Society of Clinical Oncology Gastrointestinal Symposium.

Of the respondents, 62.3% were women and 89.2% were white. Specific patient diagnoses included intrahepatic (72.5%), perihilar (13.2%), and distal (8.3%) CCA. At the time of the survey, 60.3% of patients were receiving active cancer treatment (56.9% chemotherapy, 25.2% targeted therapy, and 6.5% immunotherapy). Despite 98.5% of survey participants having health insurance, a number of respondents reported financial difficulty in pursuing medical care.

Although 77.5% of patients reported having received biomarker testing, only 27% had enrolled in a clinical trial. Respondents cited several reasons for clinical trial ineligibility:

  • Absence of trials for patients who do not have an actionable mutation (34.8%)
  • Presence of nonmeasurable tumors (17.4%)
  • Insufficient tissue biopsy (8.7%)
  • Other reasons (39.1%), including advanced age, prior chemotherapy, prior tumor resection, unavailable clinical trials in the treating cancer center, and the presence of brain metastasis or other primary cancer

Unfortunately, the clinical trial enrollment rate for patients with CCA remains low. Thus, in collaboration with all stakeholders, CCF is working with the FDA on guidance to minimize clinical trial enrollment eligibility criteria—a critical barrier leading to low enrollment rates. Moreover, CCF continues to work collaboratively with industry partners to open more clinical trials, allow expanded access programs, and design clinical trials for patients who do not have actionable mutations to provide treatment opportunities and hope for more patients with CCA.

Dr Abdel-Wahab is Chief Scientific Officer and Director of Research for the Cholangiocarcinoma Foundation (CCF), Salt Lake City, UT, and Associate Professor of Clinical Oncology at Assiut University Faculty of Medicine, Egypt. Ms Pear is a patient advocate volunteer at CCF and a master’s degree student at Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.

Related Items

Think Tank of Multidisciplinary Experts Develop Proposals to Improve Outcomes in Patients with CCA
December 2022, Vol 3, No 4
A group of 29 expert scientists and clinicians from the world’s leading academic institutions developed potentially transformative project proposals while gathered in Las Vegas for a 2-day meeting called Cure Cholangiocarcinoma Think Tank (C2T2).
International Cholangiocarcinoma Patient Registry Accelerates and Supports CCA Research
September 2022, Vol 3, No 3
The Cholangiocarcinoma Foundation hosts a patient registry, the International Cholangiocarcinoma Patient Registry (ICPR), that is a global database comprising patient medical histories and treatments for cholangiocarcinoma (CCA).
The Cholangiocarcinoma Foundation’s Patient Advocacy Initiatives
March 2022, Vol 3, No 1
At the 2022 Cholangiocarcinoma Foundation (CCF) Annual Conference on February 22-25, Melinda Bachini, Director of Advocacy of CCF, provided an update about the foundation’s advocacy and patient support initiatives. The goal of the CCF’s advocacy group is to provide educational and emotional support for the cholangiocarcinoma (CCA) community of patients and caregivers, and to empower them with the knowledge and guidance needed to self-advocate.
The International Cholangiocarcinoma Research Network: Educational and Research Achievements
By Reham Abdel-Wahab, MD, PhD
December 2021, Vol 2, No 4
In 2015, the Cholangiocarcinoma Foundation (CCF) launched the International Cholangiocarcinoma Research Network (ICRN). This network is a global collaborative of clinicians, researchers, and scientists from leading academic medical centers and research institutions working together to improve the prevention, early detection, treatment, and prognosis of cholangiocarcinoma (CCA).
New ICD-11 Codes for Cholangiocarcinoma
December 2021, Vol 2, No 4
The Cholangiocarcinoma Foundation (CCF) is encouraging healthcare professionals to support the adoption of the new International Classification of Diseases, 11th Revision (ICD-11), and its role in creating more robust epidemiological data for cholangio­carcinoma (CCA).
Navigating Compassionate Use Options for Your Patients with Cholangiocarcinoma
By Melinda Bachini
September/October 2021, Vol 2, No 3
I believe that the most powerful and positive force in medicine is that of a self-advocating patient. At the Cholangiocarcinoma Foundation, we strive to connect, educate, and empower patients with cholangiocarcinoma (CCA) to partner with their care team in navigating the course of their treatment. However, we understand that the treatment options are extremely limited for many patients with CCA.
A Watershed Moment for the Cholangiocarcinoma Community
By Stacie C. Lindsey
June/July 2021, Vol 2, No 2
In an article published last year in CCA News, I shared the Cholangiocarcinoma Foundation (CCF)’s philosophy on taking risks and leveraging collaboration over competition. The CCF was nearing its 15th anniversary, and the FDA had recently approved pemigatinib (Pemazyre), the first targeted therapy approved for cholangiocarcinoma (CCA).
The Urgent Need to Raise Awareness to Cholangiocarcinoma and Fund Research
By Teresa Delcorso-Ellmann
March 2021, Vol 2, No 1
I first learned of cholangiocarcinoma (CCA) in 2015, when my husband Steve was diagnosed with stage IV inoperable intrahepatic CCA and was given a prognosis of less than a year to live. He defied the prognosis and survived for 40 months, until his death in March 2019. When he was diagnosed, neither one of us had ever heard the word “cholangiocarcinoma” and did not know it was possible to have cancer in the bile duct. We both knew that a diagnosis of other gastrointestinal (GI) cancers, such as pancreatic or colon cancer, could be catastrophic and were stunned to realize that the treatment options and outcomes for patients with CCA were the most dismal of all GI cancers.
Where There Is Hope
By Laura R. Hnat
December 2020, Vol 1, No 3
“You have cancer.” These are the 3 little words that everyone dreads hearing and that doctors wish they never had to utter. Yet according to the American Cancer Society, an estimated 1.8 million people will be diagnosed with cancer in the United States this year, and more than 600,000 people will die of it.
Leading the Way to a Paradigm Shift in Cholangiocarcinoma: The International Cholangiocarcinoma Research Network
By Nilo Azad, MD; Mitesh J. Borad, MD
October 2020, Vol 1, No 2
In the past decade, there has been a sea change in awareness about cholangiocarcinoma (CCA). However, the standard of care has remained unchanged for more than 10 years. This year, the FDA approved a new targeted therapy, pemigatinib, which became a treatment option for approximately 10% to 15% of patients with CCA. The process of drug discovery, as well as changes in the standard of care, are becoming increasingly reliant on collaborative approaches that leverage the expertise and resources of a wide range of partners to strengthen the tools and knowledge that advance the research objectives of all stakeholders.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: